The current standard-of-care treatment for chronic phase (CP) CML is BCR-ABL-specific tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec®)29. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.